Table 4. Unadjusted and adjusted odds ratio (95% confidence interval) of MAKE 30 and one-year adverse outcomes associated with AKD stage stratified by AKI stage.

	AKI stage 1	AKI stage 2	AKI stage 3
MAKE30
Unadjusted
AKD stage 0	1.00 (reference)	1.00 (reference)	1.00 (reference)
AKD stage 1	1.82 (0.83–4.03)	1.34 (0.73–2.43)	3.14 (1.76–5.58)
AKD stage 2–3	5.53 (2.38–12.87)	14.09 (8.84–22.45)	30.88 (18.40–51.85)
Adjusted
AKD stage 0	1.00 (reference)	1.00 (reference)	1.00 (reference)
AKD stage 1	1.61 (0.66–3.94)	1.25 (0.65–2.39)	2.69 (1.46–4.97)
AKD stage 2–3	4.28 (1.39–13.16)	16.34 (9.68–27.59)	31.15 (17.98–53.96)
One-year adverse outcomes
Unadjusted
AKD stage 0	1.00 (reference)	1.00 (reference)	1.00 (reference)
AKD stage 1	1.78 (1.03–3.11)	1.21 (0.72–2.03)	1.13 (0.64–1.98)
AKD stage 2–3	4.16 (2.07–8.39)	2.71 (1.75–4.21)	2.94 (1.88–4.59)
Adjusted
AKD stage 0	1.00 (reference)	1.00 (reference)	1.00 (reference)
AKD stage 1	1.54 (0.83–2.83)	1.13 (0.62–2.03)	0.95 (0.51–1.78)
AKD stage 2–3	3.14 (1.34–7.33)	2.28 (1.38–3.77)	2.27 (1.39–3.73)

Notes.

MAKE30, Major Adverse Kidney Events within 30 days; AKD, acute kidney disease; AKI, acute kidney injury.

Multivariable logistic regression analysis was performed with adjustment for age, sex, hypertension, diabetes mellitus, cardiac infarction, congestive heart failure, chronic liver disease, chronic kidney disease, cerebrovascular disease, cancer, sepsis, organ failure, Charlson comorbidity index, anemia, proteinuria, hyperuricemia, hypoalbuminemia, cardiovascular surgery and mechanical ventilation.